Case study: treatment of a 76-year-old male patient with right anterior tibial and tibio-peroneal trunk occlusions using the Ranger™ Drug-Coated Balloon
Click here to get access to the full-length case study video now.
Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies. Our commitment is to bring forward innovative therapies that can make a difference in the lives of patients, and our foundation of more than 15 years of design and development has established our clinical leadership.
Experts challenge experts: when DCB meets DES in the SFA
Through an interactive discussion around video cases performed by expert operators, find out how renown experts challenge each other on their usage of Drug Eluting Technologies in the SFA.
February 20th, 2018. 12:30 - 14:00 CET
New 3-year data presented on the MAJESTIC trial; review of several challenging case studies; and more in the CIRSE Drug Eluting Symposium.
Prefer to read the study highlights? Read the updated MAJESTIC 3-year data (DES) and 12-month Ranger Registry (DCB).
DID YOU KNOW
Boston Scientific is the only company investing in a complete portfolio of Drug-Eluting Therapies.
The Eluvia Drug-Eluting Stent delivers unprecedented results in the SFA through its unique SUSTEND™ drug-delivery
The Ranger Drug Coated balloon has been designed to provide consistent and predictable drug delivery through efficient drug transfer and a strong coating integrity.